Liver Injury Associated with Statin Use

Patterns and Incidence of Liver Injury

Statins primarily cause a hepatocellular pattern of liver injury with transient elevations in transaminases, though cholestatic and mixed patterns can also occur, with specific patterns varying by individual statin agent 1
Elevated hepatic transaminases generally occur in 0.5% to 2.0% of patients taking statins and are dose-dependent 1, 2
Progression to liver failure specifically due to statins is exceedingly rare 1
The frequency of transaminase elevation varies by agent, with specific agents having the following incidence rates:
Agent Incidence Rate
Imatinib 6-12%
Dasatinib 50%
Nilotinib 35-62%
Bosutinib 20%
Ponatinib 56%
3
Transaminase elevations typically occur within 12-77 days of initiation of imatinib 3

CYP3A4 inhibitors, high daily dose (>100 mg), and being a substrate of CYP450 enzymes are risk factors for hepatotoxicity 4, 5
Patients with acute liver failure or decompensated cirrhosis should not take statins, while those with stable liver disease can take statins with more frequent monitoring, as recommended by the American College of Cardiology and the American Association for the Study of Liver Diseases (AASLD) 1, 6, 7, 8
Patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) are not at higher risk for serious liver injury from statins, according to the AASLD and the American College of Cardiology 1, 6, 7, 8

Regular monitoring of liver function is recommended for patients taking statins, with frequency varying by agent and patient risk factors, as recommended by the American College of Cardiology and the American Heart Association 3, 4, 1, 9
For patients taking tolvaptan, monthly monitoring for the first 18 months, then every 3 months until drug discontinuation, is recommended 4
For moderate elevations (2-3x ULN), repeat LFTs within 48-72 hours, assess for other etiologies, and consider dose reduction or temporary discontinuation based on clinical context, as recommended by Alimentary Pharmacology and Therapeutics 4, 10
For significant elevations (>3x ULN), temporarily discontinue medication, evaluate for other causes of liver injury, and consider permanent discontinuation if no other explanation is found, according to Alimentary Pharmacology and Therapeutics 4, 10
The approach to elevations involves:

Certain medications, including Clarithromycin, itraconazole, ketoconazole, fluconazole, and amiodarone, can cause transaminase elevations due to their inhibitory effects on CYP3A 4
Tolvaptan is associated with transaminase elevations >3x ULN in approximately 5% of patients with ADPKD 4
Be particularly vigilant for AST elevations in patients with pre-existing liver disease, concomitant medications that affect liver enzymes, alcohol consumption, and higher doses of atorvastatin, as advised by the American College of Cardiology and the American Heart Association 1, 2